Barclays’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-6
| Closed | -$22K | – | 4981 |
|
|
2021
Q3 | $22K | Sell |
6
-2,449,972
| -100% | -$450M | ﹤0.01% | 4366 |
|
|
2021
Q2 | $450M | Sell |
2,449,978
-1,128,398
| -32% | -$194M | 0.21% | 65 |
|
|
2021
Q1 | $547M | Buy |
3,578,376
+3,212,242
| +877% | +$497M | 0.29% | 44 |
|
|
2020
Q4 | $57.2M | Sell |
366,134
-42,407
| -10% | -$5.45M | 0.03% | 422 |
|
|
2020
Q3 | $46.8M | Buy |
408,541
+172,430
| +73% | +$18.6M | 0.03% | 415 |
|
|
2020
Q2 | $26.5M | Sell |
236,111
-149,218
| -39% | -$15.8M | 0.02% | 534 |
|
|
2020
Q1 | $34.6M | Sell |
385,329
-99,558
| -21% | -$9.77M | 0.03% | 425 |
|
|
2019
Q4 | $52.4M | Sell |
484,887
-103,943
| -18% | -$11.1M | 0.03% | 489 |
|
|
2019
Q3 | $57.7M | Buy |
588,830
+209,233
| +55% | +$23.6M | 0.04% | 408 |
|
|
2019
Q2 | $49.7M | Buy |
379,597
+112,799
| +42% | +$14.5M | 0.03% | 490 |
|
|
2019
Q1 | $36.1M | Sell |
266,798
-124,020
| -32% | -$15.4M | 0.02% | 552 |
|
|
2018
Q4 | $38M | Sell |
390,818
-80,780
| -17% | -$9.55M | 0.03% | 473 |
|
|
2018
Q3 | $65.6M | Buy |
471,598
+177,468
| +60% | +$22.3M | 0.05% | 318 |
|
|
2018
Q2 | $36.5M | Sell |
294,130
-312,897
| -52% | -$36.6M | 0.03% | 479 |
|
|
2018
Q1 | $67.7M | Buy |
607,027
+32,039
| +6% | +$3.83M | 0.05% | 319 |
|
|
2017
Q4 | $68.8M | Sell |
574,988
-59,099
| -9% | -$7.2M | 0.06% | 292 |
|
|
2017
Q3 | $89M | Sell |
634,087
-214,964
| -25% | -$29.2M | 0.09% | 175 |
|
|
2017
Q2 | $103M | Buy |
849,051
+589,735
| +227% | +$68.6M | 0.11% | 138 |
|
|
2017
Q1 | $31.4M | Buy |
259,316
+95,536
| +58% | +$12.3M | 0.03% | 386 |
|
|
2016
Q4 | $20M | Buy |
163,780
+51,137
| +45% | +$6.26M | 0.02% | 595 |
|
|
2016
Q3 | $13.8M | Sell |
112,643
-58,004
| -34% | -$7.47M | 0.02% | 697 |
|
|
2016
Q2 | $19.9M | Buy |
170,647
+68,955
| +68% | +$9.78M | 0.03% | 525 |
|
|
2016
Q1 | $14.1M | Sell |
101,692
-129,527
| -56% | -$19M | 0.02% | 610 |
|
|
2015
Q4 | $43.9M | Buy |
231,219
+72,209
| +45% | +$12.6M | 0.05% | 316 |
|
|
2015
Q3 | $24.8M | Sell |
159,010
-417,052
| -72% | -$76.1M | 0.03% | 499 |
|
|
2015
Q2 | $104M | Buy |
576,062
+359,783
| +166% | +$62.1M | 0.12% | 141 |
|
|
2015
Q1 | $37.4M | Sell |
216,279
-3,289
| -1% | -$595K | 0.04% | 413 |
|
|
2014
Q4 | $40.6M | Buy |
219,568
+8,165
| +4% | +$1.51M | 0.04% | 421 |
|
|
2014
Q3 | $34.9M | Buy |
211,403
+18,275
| +9% | +$3M | 0.03% | 461 |
|
|
2014
Q2 | $30.1M | Sell |
193,128
-9,737
| -5% | -$1.54M | 0.03% | 497 |
|
|
2014
Q1 | $30.8M | Sell |
202,865
-79,346
| -28% | -$12.6M | 0.03% | 478 |
|
|
2013
Q4 | $37.3M | Buy |
282,211
+17,600
| +7% | +$2.11M | 0.04% | 456 |
|
|
2013
Q3 | $30.7M | Buy |
264,611
+98,559
| +59% | +$10.8M | 0.04% | 468 |
|
|
2013
Q2 | $15.3M | Buy |
+166,052
| New | +$16M | 0.02% | 793 |
|
Other funds holding ALXN
Barclays's ALXN Position: Q4 2021 in Review
Barclays sold out of Alexion Pharmaceuticals (ALXN) in Q4 2021, closing a stake of 6 shares — an estimated $22K sold.
Barclays first reported a position in ALXN in Q2 2013 and held it in 34 quarters. The position peaked at $547M in Q1 2021. 2 funds tracked by Wall St. Rank hold ALXN as of Q4 2021.
- Barclays reported no remaining Alexion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Barclays sold 6 Alexion Pharmaceuticals shares in Q4 2021, an estimated $22K.
- Barclays first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Barclays's Alexion Pharmaceuticals position peaked at $547M in Q1 2021.
- 2 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.